Skip to main content

Neural Stem Cells-expressing CRAd-S-pk7

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

  • RegistryNCT05139056
  • PhasePhase 1
  • StatusRecruiting
  • ConditionCurrently Only Enrolling Glioblastoma Patients at First Recurrence
  • SponsorCity of Hope Medical Center
How Neural Stem Cells-expressing CRAd-S-pk7 worksNCT051390561 min

What the film says

Read the transcript

When glioblastoma comes back, most patients have under a year. Viruses engineered to kill cancer cells show promise, but spread poorly through brain tissue.

The idea: load the virus into cells that naturally migrate toward tumors, and let them carry it.

Neural stem cells home to gliomas. At City of Hope, banked cells are loaded with an adenovirus built to replicate only in cancer cells. During surgery to remove the recurrent tumor, the first dose goes into the cavity walls, where invading cells remain. Three more doses follow through a catheter left in place, weekly or every two weeks.

Enrolling glioblastoma at first recurrence at City of Hope, Stanford, Northwestern, and Wake Forest. Jana Portnow leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05139056

    Oncolytic virus distribution limited in brain; CRAd-S-pk7 = conditionally replicating adenovirus; First dose into resection cavity wall at surgery; three more via catheter weekly (Schedule 4) or every 2 weeks (4a); Glioblastoma at first recurrence; sites City of Hope, Stanford, Northwestern, Wake Forest (+1 more lines)

The drug

What is being tested.

PRIMARY OBJECTIVE: I. Determine the recommended maximum tolerated number of cycles (MTC) of intracavitary (ICT) administered neural stem cell-expressing CRAd-S-pk7 (NSCCRAd-S-pk7) for phase II testing based on dose-limiting toxicities (DLTs), the overall toxicity profile, and activity in patients with recurrent high-grade glioma (HGG). II.

Describe and compare the weekly dosing schedule (Treatment Schedule 4) to an every 2 week dosing schedule (Treatment Schedule 4a) of intracerebrally administered NSC-CRAd-S-pk7 based on DLTs, the overall toxicity profile, and activity in patients with glioblastoma at first recurrence. III. Determine the recommended phase 2 dose schedule based on the overall toxicity profile, and activity in patients with recurrent high grade gliomas SECONDARY OBJECTIVES: I. I.

The study

How the trial runs.

This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patient must be age >= 18 years
  • Patient has a Karnofsky performance status of >= 70%
  • Patient has a life expectancy of >= 3 months
  • When determining the maximum tolerated number of treatment cycles (MTC): patient has a histologically confirmed diagnosis of a grade 3 or 4 glioma (eg., glioblastoma, grade 4 astrocytoma, grade 3 astrocytoma, grade 3 oligodendroglioma). (This part of the study has been completed).
  • When enrolling to Treatment Schedules 4 and 4a: patient has glioblastoma at first recurrence.
  • Imaging studies show evidence of recurrent, supratentorial tumor(s).

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.